COVID-19 in transplant recipients: The Spanish experience.
Am J Transplant
; 21(5): 1825-1837, 2021 05.
Article
in English
| MEDLINE | ID: covidwho-887353
ABSTRACT
We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR] 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-ß (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR] 2.5; 95% CI 1.4-4.6), age >60 years (OR 3.7; 95% CI 2.5-5.5), and hospital-acquired COVID-19 (OR 3.0; 95% CI 1.9-4.9).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Organ Transplantation
/
Hematopoietic Stem Cell Transplantation
/
Transplant Recipients
/
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Limits:
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
English
Journal:
Am J Transplant
Journal subject:
Transplantation
Year:
2021
Document Type:
Article
Affiliation country:
Ajt.16369
Similar
MEDLINE
...
LILACS
LIS